Randomized, double-blind, placebo-controlled study of aprepitant versus two dosages of olanzapine with ondansetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving high-emetogenic chemotherapy.
Suthinee IthimakinPathra TheeratrakulApirom LaocharoenkiatAkarin NimmannitCharuwan AkewanlopNopadol SoparattanapaisarnSirisopa TechawattanawannaKrittiya KorphaisarnPongwut DanchaivijitrPublished in: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (2020)
Nausea was less severe for OLN10 than for APR in patients receiving HEC, but other measures were similar. CINV prevention efficacy was comparable between OLN5 and APR.